Feb 5, 2021

Melanoma Update, Issue 1, 2021 — Part 2: Our interview with Dr Lewis highlights the following topics as well as cases from his practice:

• Approved and investigational strategies for patients with metastatic melanoma (0:00)
• Case: A man in his late 70s with metastatic melanoma and an NRAS mutation who receives stereotactic radiosurgery and single-agent pembrolizumab (27:41)
• Case: A woman in her early 60s with metastatic melanoma and a BRAF V600 mutation who receives encorafenib and binimetinib as first-line therapy (31:04)
• Case: A man in his early 50s with metastatic melanoma and a BRAF V600 mutation (33:45)
• Therapeutic options for patients with metastatic melanoma in the first-line setting (37:45)
• Results and clinical implications of the Phase III IMspire150 trial of atezolizumab in combination with cobimetinib and vemurafenib for previously untreated advanced melanoma with a BRAF V600 mutation (44:25)
• Mechanism of action and activity of bempegaldesleukin in combination with an immune checkpoint inhibitor; rationale for the investigation of TILs for metastatic melanoma (50:16)
• Emerging data with pembrolizumab/lenvatinib for patients with advanced melanoma whose disease has progressed on an anti-PD-1/PD-L1 antibody (56:06)
• Choice of therapy for patients with BRAF wild-type metastatic melanoma (59:43)
• Activity and tolerability of ipilimumab/nivolumab for advanced melanoma (1:03:48)
• Selection and sequencing of therapy for patients with metastatic melanoma and BRAF mutations (1:08:12)
• Therapeutic approach to metastatic melanoma with a BRAF mutation and a high disease burden (1:11:36)
• Efficacy and side-effect profile of BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib) for metastatic melanoma with a BRAF mutation (1:15:39)

CME information and select publications